Patients with hip dysplasia who underwent arthroscopic labral repair experienced outcomes and failure rates similar to patients without hip dysplasia, according to results published in The American Journal of Sports Medicine.
Aaron J. Krych
“Our study demonstrates that with careful selection and modern arthroscopic techniques, dysplastic patients can benefit significantly and durably from labral repair,” Aaron J. Krych, MD, co-author of the study, told Healio.com/Orthopedics. “In our study, patients with mild dysplasia and a labral tear had similar outcomes and failure rates to rigorously matched controls at midterm follow-up extending beyond 5 plus years.”
Krych and colleagues matched patients with a lateral center edge angle of less than 25° (n=48) to patients without dysplasia (n=96) by age, sex, laterality, BMI, Tönnis grade and capsular repair. To determine predictors of outcome and failure, researchers compared VAS for pain, modified Harris hip score and hip outcome score–sports specific subscale between the two groups.
Results showed no significant differences in improvements in VAS, modified Harris hip score and hip outcome score–sports specific subscale between the dysplastic and nondysplastic groups. According to results, patients with dysplasia and controls had a 5-year failure-free survival of 83.3% and 78.1%, respectively. Researchers found no differences in survival or outcomes between patients with dysplasia who did vs. those who did not have capsular repair or when comparing lateral center edge angle of less than 20° and lateral center edge angle between 20° and 25°.
“Within the patient groups analyzed, BMI [of 30 kg/m2 or less] was associated with increased revision surgery risk. In addition, age older than 35 years and Tönnis grade 0 preoperative radiographs predicted failure to achieve the minimal clinically important difference in patient-reported outcome scores,” Krych said. “We believe these findings can assist surgeons discussing the risk and benefits of labral repair in patients with mild dysplasia, and also aid in stratifying patients in terms of known predictors of midterm outcomes.” – by Casey Tingle
Disclosures: Krych reports he receives research support from Aesculap/B. Braun, Arthritis Foundation, Ceteris and Histogenics; is a paid consultant for Arthrex, DePuy and Vericel; and receives intellectual property royalties from Arthrex. Please see the full study for a list of all other authors’ relevant financial disclosures.